Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Cristea CD, Radu M, Toboc A, Stan C, David V

Analytical biochemistry6 Oct 2023Cited by 3 (Europe PMC)

PMID37806509DOI10.1016/j.ab.2023.115336PepBankPUB-37806509

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of CJC-1295 (with DAC) aloneOther designOther
A triple quadrupole UHPLC-MS/MS method with weak cation exchange SPE detected CJC‑1295 in urine, with a limit of detection of 0.2 ng/mL and a limit of quantification of 0.6 ng/mL.
In plain wordsIn lab tests, a urine method could detect CJC‑1295 and similar peptides at very low levels.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableLimits of detection and quantification in urine
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
0.2 ng/mL
UHPLC-MS/MS urine method
LOQ
0.6 ng/mL
UHPLC-MS/MS urine method
Source sentences
Summary
is able to detect concentrations as low as 0.2 ng/mL (LOD), a limit of quantification (LOQ) at 0.6 ng/mL
1 context sentence(design, population, supporting numbers)
Summary · context
The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-3780650901
02LabNot a test of CJC-1295 (with DAC) aloneOther designOther
The urine method was linear for the tested GHRHs including CJC‑1295 across 0.1 ng/mL to 1.2 ng/mL.
In plain wordsIn lab tests, the urine method gave results in proportion to the amount of CJC‑1295 and similar peptides across a set range.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableLinear range in urine
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Linear range
0.1 to 1.2 ng/mL
UHPLC-MS/MS urine method
Source sentences
Summary
and linearity across the range of 0.1 ng/mL to 1.2 ng/mL
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-3780650902
03LabNot a test of Tesamorelin aloneOther designOther
A triple quadrupole UHPLC-MS/MS method with weak cation exchange SPE detected tesamorelin in urine, with a limit of detection of 0.2 ng/mL and a limit of quantification of 0.6 ng/mL.
In plain wordsIn lab tests, a urine method could detect tesamorelin and similar peptides at very low levels.
Peptide
Tesamorelin
Outcome
Not applicableLimits of detection and quantification in urine
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
0.2 ng/mL
UHPLC-MS/MS urine method
LOQ
0.6 ng/mL
UHPLC-MS/MS urine method
Source sentences
Summary
is able to detect concentrations as low as 0.2 ng/mL (LOD), a limit of quantification (LOQ) at 0.6 ng/mL
1 context sentence(design, population, supporting numbers)
Summary · context
The results show that the method has adequate recoveries and sensitivity, hence, it can be employed for routine screening in anti-doping laboratories.
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-3780650903
04LabNot a test of Tesamorelin aloneOther designOther
The urine method was linear for the tested GHRHs including tesamorelin across 0.1 ng/mL to 1.2 ng/mL.
In plain wordsIn lab tests, the urine method gave results in proportion to the amount of tesamorelin and similar peptides across a set range.
Peptide
Tesamorelin
Outcome
Not applicableLinear range in urine
Study
n: not reported in source
Urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Linear range
0.1 to 1.2 ng/mL
UHPLC-MS/MS urine method
Source sentences
Summary
and linearity across the range of 0.1 ng/mL to 1.2 ng/mL
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-3780650904
05LabNot a test of Sermorelin aloneOther designOther
A UHPLC-MS/MS method with weak cation exchange SPE detected GHRHs including sermorelin in urine at concentrations as low as 0.2 ng/mL.
In plain wordsA lab method detected sermorelin and related peptides in urine at concentrations as low as 0.2 ng/mL.
Peptide
Sermorelin
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
0.2 ng/mL
GHRHs in urine
Source sentences
Summary
is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is able to detect concentrations as low as 0.2 ng/mL (LOD)
1 context sentence(design, population, supporting numbers)
Summary · context
The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin)
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3780650905
06LabNot a test of Sermorelin aloneOther designOther
The method had a limit of quantification of 0.6 ng/mL for GHRHs including sermorelin in urine.
In plain wordsThe lab method could measure the amount of sermorelin and related peptides in urine down to 0.6 ng/mL.
Peptide
Sermorelin
Outcome
Not applicableLimit of quantification in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOQ
0.6 ng/mL
GHRHs in urine
Source sentences
Summary
a limit of quantification (LOQ) at 0.6 ng/mL, and linearity across the range of 0.1 ng/mL to 1.2 ng/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin)
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3780650906
07LabNot a test of Sermorelin aloneOther designOther
The method was linear across 0.1 ng/mL to 1.2 ng/mL for GHRHs including sermorelin in urine.
In plain wordsThe lab method gave a straight-line response for sermorelin and related peptides from 0.1 to 1.2 ng/mL.
Peptide
Sermorelin
Outcome
Not applicableLinearity range
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Linear range
0.1 to 1.2 ng/mL
GHRHs in urine
Source sentences
Summary
linearity across the range of 0.1 ng/mL to 1.2 ng/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin)
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3780650907
08LabNot a test of Sermorelin aloneOther designOther
The validated method had adequate recoveries and sensitivity for routine screening of GHRHs including sermorelin in anti-doping laboratories.
In plain wordsThe lab method recovered sermorelin and related peptides well enough for routine anti-doping screening.
Peptide
Sermorelin
Outcome
Not applicableRecovery and sensitivity
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
The present method developed by our doping control laboratory was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. The results show that the method has adequate recoveries and sensitivity, hence, i…
1 context sentence(design, population, supporting numbers)
Summary · context
The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, somatorelin)
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3780650908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 39Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Versions 2 to 3
9 Oct 2026, 03:13 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:13 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Summary

Results from this study8

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms

Keywords